JR...If the FDA, on the basis of the Brave study, approves Vascepa for use in AD on the basis of that study alone, Denner will sell Amarin to a BP, which can better afford to take Vascepa to new heights through marketing...If the FDA insists on a longer study, Denner will sell Amarin to a BP ,which can better afford to conduct the new study.
Either way, Amarin gets sold to a BP.
JT saw many opportunities for Amarin to GIA, but judge Du put an end to these ideas.
Market Data 
Markets 
AI
